Skip to main content
Education

Top 10 AI Companies for Digital Pathology

By January 22, 2026November 3rd, 2026No Comments

Last updated: October 2026

The leading AI companies in digital pathology for 2026 include Artera, Ibex, Tempus (which acquired Paige in 2025), Deep Bio, Primaa and Panakeia. Their tools range from FDA-authorized software that flags missed prostate cancer to algorithms that predict molecular biomarkers or treatment benefit from a routine H&E slide.

We chose these 10 because each offers AI that pathologists are using in clinical or near-clinical workflows today, not only in research. For each company, we list its focus, a notable product and any FDA milestone we could confirm. The list is alphabetical, not a ranking. Lumea is a digital pathology platform, not an AI developer, and several of these companies’ tools run inside Lumea’s viewer; we’ve noted which ones.

In this guide

Comparison at a Glance

Company Focus Notable product FDA milestone Works in Lumea’s viewer
AIRA Matrix Prostate grading and urine cytology AIRAProstate — Yes
AIxMed Computational cytology AIxURO — Yes
Artera Prostate prognosis and therapy benefit ArteraAI Prostate De Novo authorization (2025) Yes
Deep Bio Prostate grading DeepDx Prostate — Yes
Ibex Medical Analytics Prostate, breast and gastric cancer detection Ibex Prostate Detect 510(k) clearance (2025) No
Mindpeak Breast cancer IHC quantification BreastIHC — Yes
Panakeia Biomarkers from H&E slides PANProfiler Colorectal — Yes
Primaa Dermatopathology Cleo Skin — Yes
Tempus (including Paige) Cancer detection and biomarker prediction Paige Prostate, Paige Predict Paige Prostate: De Novo authorization (2021) Yes (Paige Prostate)
Valar Labs Treatment-response prediction Vesta — Yes

A dash in the FDA column means we couldn’t confirm a U.S. FDA clearance or authorization as of October 2026; many of these tools are CE marked in Europe or available for research use in the U.S. Check current status with each vendor.

The Top 10 AI Companies for Digital Pathology

Airamatrix logo

1. AIRA Matrix

Based in Mumbai, India, AIRA Matrix develops AI for cancer diagnosis, with a strong focus on prostate and bladder cancer. Its AIRAProstate tool analyzes prostate biopsies to deliver Gleason scores, ISUP grade groups, tumor percentage and perineural invasion assessment. Working with Acupath, AIRA Matrix also developed an algorithm that automates quantification of the URO17 urine test for bladder cancer.

Aixmed logo

2. AIxMed

AIxMed builds computational cytology tools that analyze cells, not just tissue. Its AIxURO product uses deep learning to identify atypical urothelial cells in urine cytology slides, supporting bladder and upper urinary tract cancer workup without an invasive procedure.

Artera ai logo

3. Artera

Artera uses multimodal AI, combining a patient’s biopsy image with clinical data, to predict long-term outcomes and which patients are likely to benefit from specific therapies. In August 2025, the FDA granted De Novo authorization to ArteraAI Prostate, the first AI software authorized to predict long-term outcomes for patients with non-metastatic prostate cancer.

Deep bio logo

4. Deep Bio

Based in South Korea, Deep Bio develops deep learning software for cancer diagnosis. Its DeepDx Prostate tool detects cancer in prostate core biopsies, grades it on the Gleason system and measures tumor and tissue length, analyzing a whole slide in under 30 seconds. It is approved for clinical use in South Korea and Switzerland and available for research use in the U.S.

Ibex logo

5. Ibex Medical Analytics

Ibex describes its platform as the most widely deployed AI in pathology, with solutions for prostate, breast and gastric biopsies. In February 2025, Ibex Prostate Detect received FDA 510(k) clearance as a safety net that helps pathologists find small or rare prostate cancers they might otherwise miss.

Mindpeak logo

6. Mindpeak

Based in Hamburg, Germany, Mindpeak develops AI that automates repetitive quantification work in pathology. Its BreastIHC software detects and quantifies breast cancer cells on immunohistochemistry slides and is CE-IVD marked for primary diagnosis in Europe.

Panakeia logo

7. Panakeia

Based in Cambridge, U.K., Panakeia predicts molecular biomarkers directly from routine H&E slides. Its PANProfiler Colorectal determines MSI/MMR status in minutes rather than the weeks a conventional lab test can take, and it is UKCA-marked for clinical use in the U.K.

Primaa logo

8. Primaa

Founded in 2018 in Paris, Primaa builds AI for breast pathology and dermatopathology. Its Cleo Skin tool helps triage the four most common skin lesions (melanoma, nevus, basal cell carcinoma and squamous cell carcinoma), detects mitoses and perineural invasion, and measures lesion margins and dimensions. For more on dermatopathology AI, see our list of top AI companies for dermatopathology.

Tempus logo

9. Tempus (including Paige)

Tempus applies AI across a large library of clinical and molecular data to support precision medicine. In August 2025, it completed its acquisition of Paige, whose Paige Prostate was the first FDA-authorized AI product in pathology (2021) and was built on Memorial Sloan Kettering Cancer Center’s digital slide archive. In 2026, Tempus launched Paige Predict, which analyzes a single H&E slide to predict the likelihood of 123 biomarkers and molecular pathways across 16 cancer types.

Valar labs logo

10. Valar Labs

Founded in 2021 by a team that met at Stanford, Valar Labs uses AI on routine H&E slides to predict how patients will respond to treatment. Its Vesta bladder test identifies patients with non-muscle invasive bladder cancer who are unlikely to benefit from BCG therapy and stratifies their risk of recurrence and progression; in 2026 the FDA granted Breakthrough Device designation to Vesta Bladder Risk Stratify Dx. Valar also offers tests for prostate and pancreatic cancer.

Looking for AI specific to prostate biopsies? See our guide to AI for prostate pathology.

How to Evaluate a Pathology AI Tool

  • Intended use and regulatory status: Is it FDA-cleared or authorized for the use you have in mind, CE marked, or research use only? Clinical use outside a cleared indication means your lab validates it as a laboratory-developed test.
  • Evidence on cases like yours: Ask for validation data on your specimen types, stains and scanners, and plan to test it on your own cases.
  • Where the results appear: If using the AI means leaving your viewer, adoption suffers. Ask whether results show up alongside the slide where you sign out.
  • Cost and reimbursement: Understand pricing per case or per slide, and whether any of it is reimbursable.
  • The pathologist stays in charge: Every tool on this list supports pathologists rather than replacing them.

For a step-by-step plan, see How to Implement Digital Pathology.

How Lumea Works with AI Partners

An algorithm is only as useful as the platform it runs in. Lumea isn’t an AI developer. It’s the digital pathology platform where AI runs. Lumea’s Viewer+ is an open platform, so labs can choose the best AI for each specialty instead of being locked into one vendor’s algorithms.

AI tools from partners including Tempus’s Paige Prostate, Artera, Primaa, Deep Bio, AIRA Matrix, AIxMed and Panakeia run inside the same viewer where pathologists review slides and sign out, so there’s no separate application to open. A urology practice’s lab can have Paige Prostate’s cancer detection on its prostate biopsies, while a dermatopathology group uses Primaa’s Cleo Skin, all in one workflow.

See every available tool in Lumea’s Partner Marketplace.

Honorable Mentions

Aiforia
Aiforia develops AI-powered pathology image analysis software for clinical and research workflows. Its offering combines quantitative AI models with image review, case-level reporting, and laboratory-system integration. Aiforia Create, intended for research use only, also enables pathologists and other domain experts to build and evaluate deep-learning models for image-analysis tasks.

Aignostics
A spin-off from Charité – Universitätsmedizin Berlin, Aignostics builds custom pathology AI models for pharmaceutical and biotech companies, from research through clinical trials.

DoMore Diagnostics
Oslo-based DoMore Diagnostics developed Histotype Px Colorectal, a CE-IVD marked algorithm that predicts colorectal cancer patient outcomes from routine H&E slides.

Owkin
Owkin applies AI to drug discovery and diagnostics. Its MSIntuit CRC is a CE-IVD marked tool that pre-screens colorectal cancer H&E slides for microsatellite instability (MSI).

PathAI
Boston-based PathAI develops AI for pathology and runs the AISight Dx image management platform, which received FDA 510(k) clearance for primary diagnosis in 2025.

Qritive
Singapore-based Qritive develops AI modules for prostate and colon cancer, lymph node metastasis and IHC quantification, including QAi Prostate Grade.

Sonrai Analytics
A Belfast-based spinout from Queen’s University, Sonrai Analytics combines pathology images with multi-omic and clinical data to support precision medicine research and diagnostics.

Stratipath
Stockholm-based Stratipath developed Stratipath Breast, a CE-IVD marked tool that sorts breast cancer patients into low- and high-risk groups from routine H&E slides.

Techcyte
Founded in 2013 in Orem, Utah, Techcyte offers Fusion, an AI platform for anatomic and clinical pathology that is currently for research use only in the U.S.

Frequently Asked Questions

Which AI is best for pathology?

There isn’t one best tool; it depends on the specialty and task. For prostate biopsies, FDA-cleared or authorized options include Paige Prostate and Ibex Prostate Detect for cancer detection, and ArteraAI Prostate for prognosis. Dermatopathology, cytology and biomarker prediction each have their own specialists. Start with your highest-volume specimen type and the step where your pathologists spend the most time.

Are there FDA-approved AI tools for pathology?

Yes. The FDA has cleared or authorized a small number of pathology AI tools, starting with Paige Prostate in 2021. More recent examples include Ibex Prostate Detect (510(k), 2025) and ArteraAI Prostate (De Novo, 2025). Many other tools are CE marked in Europe or available for research use only in the U.S.

Will AI replace pathologists?

No. Today’s pathology AI flags areas to review, quantifies features and predicts biomarkers, but the pathologist makes the diagnosis. With demand for pathology growing faster than the workforce, AI is better understood as a way to extend pathologists’ capacity.

How do labs add AI to their workflow?

Most labs first go digital for primary diagnosis, then add AI one use case at a time, validating each on their own cases. Choosing a platform that runs third-party AI inside the viewer makes adding tools easier later.

See AI in Your Workflow

Want to see how these tools work alongside your own cases? Request a demo of Lumea’s Viewer+ and Partner Marketplace.

author avatar
Abigail Diepeveen Senior Director of Growth & Digital Strategy
Abigail Diepeveen is Senior Director of Growth & Digital Strategy at Lumea, where she has spent nearly a decade working at the intersection of digital pathology technology and the labs, pathologists, and clinicians who use it. She holds a Master of Science in Marketing with a Digital Marketing specialization from Western Governors University.

Leave a Reply

Stay current in digital pathology — subscribe to the Digital Diagnostic Digest Subscribe Free → ✕